Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to -$34.7 billion.

  • Astrazeneca's Non-Current Debt rose 158.65% to -$34.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$34.7 billion, marking a year-over-year increase of 158.65%. This contributed to the annual value of -$34.7 billion for FY2025, which is 158.65% up from last year.
  • As of Q4 2025, Astrazeneca's Non-Current Debt stood at -$34.7 billion, which was up 158.65% from -$34.4 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Non-Current Debt high stood at $28.1 billion for Q4 2021, and its period low was -$43.7 billion during Q3 2021.
  • For the 5-year period, Astrazeneca's Non-Current Debt averaged around -$24.1 billion, with its median value being -$32.2 billion (2022).
  • Its Non-Current Debt has fluctuated over the past 5 years, first surged by 21914.62% in 2021, then tumbled by 25782.7% in 2024.
  • Astrazeneca's Non-Current Debt (Quarter) stood at $28.1 billion in 2021, then dropped by 18.37% to $23.0 billion in 2022, then decreased by 2.61% to $22.4 billion in 2023, then tumbled by 257.83% to -$35.3 billion in 2024, then grew by 1.59% to -$34.7 billion in 2025.
  • Its Non-Current Debt stands at -$34.7 billion for Q4 2025, versus -$34.4 billion for Q3 2025 and -$24.7 billion for Q2 2025.